Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 526

Results For "MP"

10148 News Found

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr
News | February 02, 2024

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023


Orchid Pharma's Exblifeb granted EMA approval
Drug Approval | February 01, 2024

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia


Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24
News | February 01, 2024

Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24

Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth


Glenmark partners Pfizer to launch Abrocitinib in India
Drug Approval | February 01, 2024

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India


Zydus Lifesciences launches Rexigo
News | February 01, 2024

Zydus Lifesciences launches Rexigo

This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India


Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr
News | February 01, 2024

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023


AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
Clinical Trials | January 31, 2024

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation


Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Drug Approval | January 31, 2024

Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours

Submission to be reviewed under FDA real-time oncology review and Project Orbis


Covestro’s new medical polycarbonate pushes the boundaries of heat resistance
News | January 30, 2024

Covestro’s new medical polycarbonate pushes the boundaries of heat resistance

Combines biocompatibility, heat-resistance, transparency and durability